In Vitro Diagnostic Assay to Detect SARS-CoV-2-Neutralizing Antibody in Patient Sera Using Engineered ACE-2 Mini-Protein
Authors:
- Bruna Andersen Pereira de JesusBJBruna Andersen Pereira de Jesus
- Anderson Albino GomesAGAnderson Albino Gomes
- Alex E. ClarkACAlex E. Clark
- Tayse Andrade RodriguesTRTayse Andrade Rodrigues
- Melissa Ledgerwood-LeeMLMelissa Ledgerwood-Lee
- Westley Van ZantWestley Van Zant
- Howard BricknerHBHoward Brickner
- Meiqiao WangMWMeiqiao Wang
- David L. BlumDBDavid L. Blum
- Maria B. CasseraMCMaria B. Cassera
- Aaron F. CarlinACAaron F. Carlin
- Eliah S. Aronoff-SpencerEAEliah S. Aronoff-Spencer
Open Access
Abstract
The recent development and mass administration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) vaccines allowed for disease control, reducing hospitalizations and mortality. Most of these vaccines target the SARS-CoV-2 Spike (S) protein antigens, culminating with the production of neutralizing antibodies (NAbs) that disrupt the attachment of the virus to ACE2 receptors on the host cells. However, several studies demonstrated that the NAbs typically rise within a few weeks after vaccination but quickly reduce months later. Thus, multiple booster administration is recommended, leading to vaccination hesitancy in many populations. Detecting serum anti-SARS-CoV-2 NAbs can instruct patients and healthcare providers on correct booster strategies. Several in vitro diagnostics kits are available; however, their high cost impairs the mass NAbs diagnostic testing. Recently, we engineered an ACE2 mimetic that interacts with the Receptor Binding Domain (RBD) of the SARS-2 S protein. Here we present the use of this engineered mini-protein (p-deface2 mut) to develop a detection assay to measure NAbs in patient sera using a competitive ELISA assay. Serum samples from twenty-one patients were tested. Nine samples (42.8%) tested positive, and twelve (57.1%) tested negative for neutralizing sera. The data correlated with the result from the standard commercial assay that uses human ACE2 protein. This confirmed that p-deface2 mut could replace human ACE2 in ELISA assays. Using bacterially expressed p-deface2 mut protein is cost-effective and may allow mass SARS-CoV-2 NAbs detection, especially in low-income countries where economical diagnostic testing is crucial. Such information will help providers decide when a booster is required, reducing risks of reinfection and preventing the administration before it is medically necessary.Keywords
Funding Information
- Career Award for Medical Scientists from the Burroughs Wellcome Fund
This publication has 37 references indexed in Scilit:
- COVID-19: Significance of antibodiesHuman Antibodies, 2020
- Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humansNature Microbiology, 2020
- Seroprevalence of anti‐SARS‐CoV‐2 antibodies in COVID‐19 patients and healthy volunteers up to 6 months post disease onsetEuropean Journal of Immunology, 2020
- SARS-CoV-2 vaccines in developmentNature, 2020
- A perspective on potential antibody-dependent enhancement of SARS-CoV-2Nature, 2020
- A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2Science, 2020
- Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019Clinical Infectious Diseases, 2020
- Patterns of IgG and IgM antibody response in COVID-19 patientsEmerging Microbes & Infections, 2020
- Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routesEmerging Microbes & Infections, 2020
- Antibody responses to viral infections: a structural perspective across three different enveloped virusesNature Microbiology, 2019